Characteristics of patients with chemotherapy-induced oral mucositis
| Chemotherapy-induced oral mucositis (n=19) | |
| Median age, years (range) | 64 (37–83) |
| Sex (male/female) | 17/2 |
| ECOG PS | |
| 0 | 8 (42.1%) |
| 1 | 10 (52.6%) |
| 2 | 1 (5.3%) |
| CTCAE grade of the oral mucositis | |
| 1 | 14 (73.7%) |
| 2 | 5 (26.3%) |
| No of lesions | |
| Single | 9 (47.4%) |
| Multiple | 10 (52.6%) |
| Lesion site of oral mucositis | |
| Oral membrane | |
| Buccal mucosa | 7 (36.8%) |
| Palate | 4 (21.1%) |
| Labial mucosa | 10 (52.6%) |
| Floor of mouth | 1 (5.3%) |
| Gum | 2 (10.5%) |
| Tongue | 6 (31.6%) |
| Disease | |
| Oesophageal cancer | 2 (10.5%) |
| Gastric cancer | 4 (21.1%) |
| Colorectal cancer | 8 (42.1%) |
| Pancreatic cancer | 3 (15.8%) |
| Neuroendocrine tumour | 2 (10.5%) |
| Anticancer agent | |
| Fluoropyrimidine | 12 (63.2%) |
| Platinum | 7 (36.8%) |
| Taxane | 3 (15.8%) |
| Anti-VEGF | 4 (21.1%) |
| Anti-EGFR | 4 (21.1%) |
| Gemcitabine | 2 (10.5%) |
| Sunitinib | 1 (5.3%) |
| Everolimus | 1 (5.3%) |
| Mitomycin | 1 (5.3%) |
CTCAE, Common Terminology Criteria for Adverse Events V.4.0; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; PS, performance status; ; VEGF, vascular endothelial growth factor.